Fig 1.
SSNHL patients were identified according to pre-specified criteria. Patients were excluded from further chart review and analysis if they received additional diagnoses of vestibular schwannoma or Meniere’s disease, chemotherapy within 4 weeks of symptom onset, did not have record of symptom onset or initial IT date, or had incomplete audiometric data.
Fig 2.
Data collection methodology including demographic, risk factor, medical comorbidity, and SSNHL information.
Table 1.
Summarized descriptive statistics of demographic, social determinants of health, risk factors, comorbidities, and detailed SSNHL-specific findings.
Table 2.
Mean values of treatment interventions according to recovery group.
Fig 3.
Treatment latency breakpoint independent of systemic steroid treatment.
Segmented regression analysis revealed a significant breakpoint at 18 (SE: 2.92) days from SSNHL symptom onset to receipt of first IT steroid injection, where significantly worse PTA recovery was seen in patients initiating IT steroid treatment after this interval (p < 0.001).